ArticleJournal of clinical medicine2025
Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors.
Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Genetic Variation inInternational journal of molecular sciences · 2026Article
- Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.International journal of cancer · 2026Observational
- Efficacy and tolerability of CDK 4/6 inhibitors in HR-positive HER2-negative de novo metastatic breast cancer patients aged ≥ 70 years.BMC cancer · 2026Article
- Efficacy and safety of dalpiciclib combined with endocrine therapy in elderly patients with HRFrontiers in oncology · 2026Article
- Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer.Cancer chemotherapy and pharmacology · 2025Article
- Baseline neutrophil-lymphocyte ratio (NLR) predicts toxicity and survival in HR+/HER-2 breast cancer patients treated with CDK4/6 inhibitors.Breast (Edinburgh, Scotland) · 2025Article
- A real-world study of palbociclib plus endocrine therapy with or without a short course chemotherapy in the first-line treatment of HR-positive HER2-negative metastatic breast cancer.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.